1:02 | Can you combine a pan-RAS inhibitor with an allele-specific inhibitor? We also know that many resistance mutations that develop after KRAS G12D therapy, based on the KRAS G12C data published ...

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

Marfan syndrome (MFS) is an inherited disorder caused by mutations in the FBN1 gene encoding fibrillin-1, a matrix component of extracellular microfibrils. The main cause of morbidity and mortality in ...

1Department of Oncology, University of Oxford, Oxford, United Kingdom. *Corresponding Author: Connor E. Woolley, Department of Oncology, University of Oxford, Old Road Campus Research Building, ...

The multicenter, open-label, randomized CodeBreaK 300 trial included 160 patients with KRAS G12C-mutated mCRC.1,2 Investigators compared Lumakras at doses of 960 mg and 240 mg in combination with ...

Am­gen’s Lumakras has se­cured an FDA ap­proval in com­bi­na­tion with the drug­mak­er’s Vectibix for a sub­set of pa­tients with metasta­t­ic col­orec­tal can­cer, mark­ing a ...

This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic ... compared to 2 months (1.9, 3.9) on investigator's choice ...

GuruFocus has detected 6 Warning Signs with AMGN. The decision, announced Thursday, applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300, a phase 3 ...

NEW YORK – The US Food and Drug Administration on Thursday approved Amgen's KRAS inhibitor Lumakras (sotorasib) with its EGFR monoclonal antibody Vectibix (panitumumab) for previously treated patients ...